Q-omics provides the consensus-scored CCDC14 profile across patient tissues and cancer cell-line models. CCDC14 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CCDC14 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, CCDC14 RNA expression shows 20,697 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where CCDC14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC14 survival associations across molecular data types. CCDC14 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC14 RNA expression–survival associations across cancer types. High CCDC14 expression shows unfavorable associations in ACC, KIRC, MESO and KICH, but favorable associations in BLCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CCDC14 RNA expression.
This table summarizes CCDC14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC14 shows higher tumor expression in HNSC, KIRC, BLCA, LIHC, KIRP and STAD. The HNSC box plot shows higher CCDC14 RNA expression in tumor versus normal tissue (log2 FC = +1.303, t-test p < 0.001).
This table shows molecular features associated with CCDC14 in patient tissues and cancer cell lines. In patient samples, CCDC14 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
